Olivier Benveniste

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2953858/publications.pdf

Version: 2024-02-01

162 papers	9,534 citations	31976 53 h-index	45317 90 g-index
173 all docs	173 docs citations	173 times ranked	7547 citing authors

#	Article	IF	Citations
1	Correspondence on â€˜Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric surveyâ€™. Annals of the Rheumatic Diseases, 2023, 82, e30-e30.	0.9	11
2	Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19. Archives of Cardiovascular Diseases, 2022, 115, 96-96.	1.6	1
3	Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144, 353-372.	7.7	19
4	Endoplasmic reticulumâ€stress and unfolded protein responseâ€activation in immuneâ€mediated necrotizing myopathy. Brain Pathology, 2022, 32, .	4.1	7
5	Cytokine profile as a prognostic tool in coronavirus disease 2019. Comment on â€œUrgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndromeâ€by Quartuccio et al. Joint Bone Spine. 2020;87:191â€“93. Joint Bone Spine, 2021, 88, 105074.	1.6	5
6	Global versus individual muscle segmentation to assess quantitative MRI-based fat fraction changes in neuromuscular diseases. European Radiology, 2021, 31, 4264-4276.	4.5	19
7	Antiphospholipid antibodies and thrombotic events in COVID-19 patients hospitalized in medicine ward. Autoimmunity Reviews, 2021, 20, 102729.	5.8	26
8	Sirolimus for treatment of patients with inclusion body myositis: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial. Lancet Rheumatology, The, 2021, 3, e40-e48.	3.9	32
9	The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. Autoimmunity Reviews, 2021, 20, 102788.	5.8	17
10	The role of interferons type I, II and III in myositis: A review. Brain Pathology, 2021, 31, e12955.	4.1	44
11	MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathology, 2021, 31, e12954.	4.1	27
12	NanoString technology distinguishes antiâ€TIFâ€1Î³⁺ from antiâ€Miâ€2⁺ dermatomyositis patients. Brain Pathology, 2021, 31, e12957.	4.1	11
13	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. Therapie, 2021, 76, 285-295.	1.0	8
14	Nonsystemic vasculitic neuropathy: Presentation and long-term outcome from a French cohort of 50 patients. Autoimmunity Reviews, 2021, 20, 102874.	5.8	2
15	NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Cells, 2021, 10, 2551.	4.1	8
16	Lean regional muscle volume estimates using explanatory bioelectrical models in healthy subjects and patients with muscle wasting. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 39-51.	7.3	6
17	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14â€“16 December 2018. Neuromuscular Disorders, 2020, 30, 70-92.	0.6	148
18	Sequestosomeâ€1 (p62) expression reveals chaperoneâ€assisted selective autophagy in immuneâ€mediated necrotizing myopathies. Brain Pathology, 2020, 30, 261-271.	4.1	42

#	Article	IF	Citations
19	Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients. Autoimmunity Reviews, 2020, 19, 102465.	5.8	14
20	Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. Multiple Sclerosis and Related Disorders, 2020, 38, 101869.	2.0	14
21	Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients. PLoS ONE, 2020, 15, e0240711.	2.5	54
22	Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. Seminars in Arthritis and Rheumatism, 2020, 50, 1140-1149.	3.4	14
23	Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nature Reviews Rheumatology, 2020, 16, 689-701.	8.0	131
24	Neurological diseases of unknown etiology: Brain-biopsy diagnostic yields and safety. European Journal of Internal Medicine, 2020, 80, 78-85.	2.2	18
25	Response to: Comment on â€œSystematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancyâ€• Journal of the American Academy of Dermatology, 2020, 83, e461-e462.	1.2	1
26	Response to: â€˜On using machine learning algorithms to define clinically meaningful patient subgroupsâ€™ by Pinal-Fernandez and Mammen. Annals of the Rheumatic Diseases, 2020, 79, e130-e130.	0.9	0
27	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology, 2020, 95, e70-e78.	1.1	142
28	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmunity Reviews, 2020, 19, 102586.	5.8	80
29	Rituximab and Cyclophosphamide in Antisynthetase Syndromeâ€“related Interstitial Lung Disease: An Observational Retrospective Study. Journal of Rheumatology, 2020, 47, 1678-1686.	2.0	18
30	Severe axial and pelvifemoral muscle damage in immune-mediated necrotizing myopathy evaluated by whole-body MRI. Seminars in Arthritis and Rheumatism, 2020, 50, 1437-1440.	3.4	28
31	Routine monitoring of isometric knee extension strength in patients with muscle impairments using a new portable device: cross-validation against a standard isokinetic dynamometer. Physiological Measurement, 2020, 41, 015003.	2.1	7
32	Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy. Journal of the American Academy of Dermatology, 2020, 83, 1759-1763.	1.2	18
33	Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis. Brain Pathology, 2020, 30, 867-876.	4.1	13
34	Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight, 2020, 5, .	5.0	65
35	Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. PLoS ONE, 2020, 15, e0233460.	2.5	9
36	Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. PLoS ONE, 2020, 15, e0242306.	2.5	10

#	Article	IF	Citations
37	Title is missing!. , 2020, 15, e0233460.		0
38	Title is missing!. , 2020, 15, e0233460.		0
39	Title is missing!. , 2020, 15, e0233460.		0
40	Title is missing!. , 2020, 15, e0233460.		0
41	Title is missing!. , 2020, 15, e0240711.		0
42	Title is missing!. , 2020, 15, e0240711.		0
43	Title is missing!. , 2020, 15, e0240711.		0
44	Title is missing!. , 2020, 15, e0240711.		0
45	Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurology, The, 2019, 18, 834-844.	10.2	91
46	Reply: Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain, 2019, 142, e60-e60.	7.6	3
47	Inclusion body myositis: accumulation of evidence for its autoimmune origin. Brain, 2019, 142, 2549-2551.	7.6	12
48	Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain, 2019, 142, e9-e9.	7.6	1
49	Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice. Journal of Neuromuscular Diseases, 2019, 6, 99-107.	2.6	7
50	Biomarkers in Inflammatory Myopathiesâ€"An Expanded Definition. Frontiers in Neurology, 2019, 10, 554.	2.4	48
51	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Annals of the Rheumatic Diseases, 2019, 78, 996-1002.	0.9	81
52	PD1 pathway in immune-mediated myopathies. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e558.	6.0	42
53	Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome. Journal of Neuroimmunology, 2019, 332, 212-215.	2.3	13
54	The IgG2 Isotype of Antiâ€"Transcription Intermediary Factor 1Î³ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis. Arthritis and Rheumatology, 2019, 71, 1360-1370.	5.6	33

#	Article	IF	Citations
55	Autoantibody testing in idiopathic inflammatory myopathies. Practical Neurology, 2019, 19, 284-294.	1.1	16
56	CD8+T-bet+ cells as a predominant biomarker for inclusion body myositis. Autoimmunity Reviews, 2019, 18, 325-333.	5.8	21
57	Comparison of MR T1 and T2 mapping parameters to characterize myocardial and skeletal muscle involvement in systemic idiopathic inflammatory myopathy (IIM). European Radiology, 2019, 29, 5139-5147.	4.5	19
58	Sirolimus and mTOR Inhibitors: A Review of Side Effects and Specific Management in Solid Organ Transplantation. Drug Safety, 2019, 42, 813-825.	3.2	78
59	Expanding the spectrum of HIV-associated myopathy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1296-1298.	1.9	7
60	Autoantibodies at the Center of (sub)Classificationâ€"Issues of Detectionâ€"Reply. JAMA Neurology, 2019, 76, 868.	9.0	0
61	Of the importance of the clinical phenotypes in the interpretation of the studies dealing with Fabry disease. Orphanet Journal of Rare Diseases, 2019, 14, 4.	2.7	2
62	Infliximab as effective treatment for aseptic neutrophilic myositis. Neurology, 2019, 93, 1009-1011.	1.1	0
63	Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e523.	6.0	66
64	Rituximab in the Treatment of Refractory Anti-HMGCR Immune-mediated Necrotizing Myopathy. Journal of Rheumatology, 2019, 46, 623-627.	2.0	36
65	Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmunity Reviews, 2019, 18, 223-230.	5.8	44
66	In vivopathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Annals of the Rheumatic Diseases, 2019, 78, 131-139.	0.9	97
67	Local Texture Anisotropy as an Estimate of Muscle Quality in Ultrasound Imaging. Ultrasound in Medicine and Biology, 2018, 44, 1133-1140.	1.5	18
68	Necrosis in anti-SRP ⁺ and anti-HMGCR ⁺ myopathies. Neurology, 2018, 90, e507-e517.	1.1	132
69	Muscle Shear Wave Elastography in Inclusion Body Myositis: Feasibility, Reliability and Relationships with Muscle Impairments. Ultrasound in Medicine and Biology, 2018, 44, 1423-1432.	1.5	30
70	Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e451.	6.0	19
71	Anti-mitochondrial antibodies are not a hallmark of severity in idiopathic inflammatory myopathies. Joint Bone Spine, 2018, 85, 375-376.	1.6	14
72	The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Annals of the Rheumatic Diseases, 2018, 77, 30-39.	0.9	183

#	Article	IF	Citations
73	Clinical and multi-omics cross-phenotyping of patients with autoimmune and autoinflammatory diseases: the observational TRANSIMMUNOM protocol. BMJ Open, 2018, 8, e021037.	1.9	17
74	Immune Checkpoint Inhibitorâ€“Associated Myositis. Circulation, 2018, 138, 743-745.	1.6	139
75	Dermoskeletics to preserve mobility and function in inclusion body myositis. Neurology, 2018, 91, 760-760.	1.1	3
76	Reply: A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain, 2018, 141, e81-e81.	7.6	4
77	Peculiar clinicopathological features of immune-mediated necrotizing myopathies. Current Opinion in Rheumatology, 2018, 30, 655-663.	4.3	16
78	Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurology, 2018, 75, 1528.	9.0	301
79	Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY. Orphanet Journal of Rare Diseases, 2018, 13, 127.	2.7	19
80	Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies. Current Rheumatology Reports, 2018, 20, 56.	4.7	10
81	Non-invasive differentiation of idiopathic inflammatory myopathy with cardiac involvement from acute viral myocarditis using cardiovascular magnetic resonance imaging T1 and T2 mapping. Journal of Cardiovascular Magnetic Resonance, 2018, 20, 11.	3.3	42
82	JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain, 2018, 141, 1609-1621.	7.6	169
83	Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology, 2018, 91, e985-e994.	1.1	247
84	Efficacy of Rituximab in Refractory Generalized anti-AChR Myasthenia Gravis. Journal of Neuromuscular Diseases, 2018, 5, 241-249.	2.6	31
85	Analysis of cell surface and intranuclear markers on non-stimulated human PBMC using mass cytometry. PLoS ONE, 2018, 13, e0194593.	2.5	26
86	La myosite Ã inclusions. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 91-103.	0.0	0
87	Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy. Annals of Hematology, 2017, 96, 695-696.	1.8	15
88	Immuneâ€Array Analysis in Sporadic Inclusion Body Myositis Reveals HLAâ€“DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. Arthritis and Rheumatology, 2017, 69, 1090-1099.	5.6	41
89	Pathogenic role of antiâ€“signal recognition protein and antiâ€“3â€Hydroxyâ€3â€methylglutarylâ€<scp>C</scp>o<scp>A</scp> reductase antibodies in necrotizing myopathies: Myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Annals of Neurology, 2017, 81, 538-548.	5.3	112
90	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. Journal of Autoimmunity, 2017, 79, 84-90.	6.5	67

#	Article	IF	Citations
91	IFN-Î²-induced reactive oxygen species and mitochondrial damage contribute to muscle impairment and inflammation maintenance in dermatomyositis. Acta Neuropathologica, 2017, 134, 655-666.	7.7	78
92	Physical activity monitoring: A promising outcome measure in idiopathic inflammatory myopathies. Neurology, 2017, 89, 101-103.	1.1	16
93	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis and Rheumatology, 2017, 69, 898-910.	5.6	52
94	Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients. Neuromuscular Disorders, 2017, 27, 251-258.	0.6	41
95	Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance. Current Opinion in Neurology, 2017, 30, 457-463.	3.6	30
96	Response to: â€˜Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteriaâ€™ by Cavagnaet al. Annals of the Rheumatic Diseases, 2017, 77, annrheumdis-2017-212382.	0.9	2
97	Value of biomarkers for predicting immunoglobulin A vasculitis nephritis outcome in an adult prospective cohort. Nephrology Dialysis Transplantation, 2017, 33, 1579-1590.	0.7	37
98	Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA. Journal of Neuromuscular Diseases, 2016, 3, 67-75.	2.6	44
99	Advances in serological diagnostics of inflammatory myopathies. Current Opinion in Neurology, 2016, 29, 662-673.	3.6	96
100	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18â€“20 September 2015. Neuromuscular Disorders, 2016, 26, 523-534.	0.6	19
101	High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain, 2016, 139, 2131-2135.	7.6	202
102	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. Autoimmunity Reviews, 2016, 15, 983-993.	5.8	105
103	Involvement of NK Cells and NKp30 Pathway in Antisynthetase Syndrome. Journal of Immunology, 2016, 197, 1621-1630.	0.8	26
104	The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies. Journal of Autoimmunity, 2016, 75, 118-129.	6.5	34
105	Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. Acta Neuropathologica Communications, 2016, 4, 45.	5.2	52
106	Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies. American Journal of Pathology, 2016, 186, 691-700.	3.8	78
107	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. Annals of the Rheumatic Diseases, 2016, 75, 1558-1566.	0.9	127
108	Expanding the spectrum of livedoid vasculopathy: peculiar neuromuscular manifestations. Neuropathology and Applied Neurobiology, 2015, 41, 849-852.	3.2	12

#	Article	IF	Citations
109	Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. PLoS ONE, 2015, 10, e0133702.	2.5	84
110	Nuclear actin aggregation is a hallmark of anti-synthetase syndromeâ€“induced dysimmune myopathy. Neurology, 2015, 84, 1346-1354.	1.1	90
111	Anti-Jo-1 antibody-positive patients show a characteristic necrotizing perifascicular myositis. Brain, 2015, 138, 2485-2492.	7.6	134
112	Quickly progressive amyotrophy of the thigh: An unusual cause of rapid chondrolysis of the knee. Joint Bone Spine, 2015, 82, 203-205.	1.6	3
113	Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathologica, 2015, 129, 611-624.	7.7	112
114	Th1 Response and Systemic Treg Deficiency in Inclusion Body Myositis. PLoS ONE, 2014, 9, e88788.	2.5	65
115	Sporadic late-onset nemaline myopathy with MGUS. Neurology, 2014, 83, 2133-2139.	1.1	40
116	Interferonâ€Î± Inhibition by Intravenous Immunoglobulin Is Independent of Modulation of the Plasmacytoid Dendritic Cell Population in the Circulation: Comment on the Article by Wiedeman et al. Arthritis and Rheumatology, 2014, 66, 2308-2309.	5.6	2
117	Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy. Acta Neuropathologica Communications, 2014, 2, 154.	5.2	68
118	Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies. Journal of Immunology Research, 2014, 2014, 1-8.	2.2	41
119	Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Research and Therapy, 2014, 16, R39.	3.5	57
120	Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials. Neuromuscular Disorders, 2014, 24, 604-610.	0.6	41
121	Anti-HMGCR Autoantibodies in European Patients With Autoimmune Necrotizing Myopathies. Medicine (United States), 2014, 93, 150-157.	1.0	235
122	Expression of myogenic regulatory factors and myo-endothelial remodeling in sporadic inclusion body myositis. Neuromuscular Disorders, 2013, 23, 75-83.	0.6	32
123	HTLV-1-associated inflammatory myopathies: Low proviral load and moderate inflammation in 13 patients from West Indies and West Africa. Journal of Clinical Virology, 2013, 57, 70-76.	3.1	17
124	Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival. European Respiratory Journal, 2013, 42, 1271-1282.	6.7	108
125	Acquired necrotizing myopathies. Current Opinion in Neurology, 2013, 26, 554-560.	3.6	68
126	Beneficial Role of Rapamycin in Experimental Autoimmune Myositis. PLoS ONE, 2013, 8, e74450.	2.5	27

#	Article	IF	Citations
127	Gene therapy, an ongoing revolution. Blood, 2012, 119, 2973-2974.	1.4	5
128	A phase I trial of adeno-associated virus serotype 1-Î³-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain, 2012, 135, 483-492.	7.6	78
129	Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmunity Reviews, 2012, 12, 210-217.	5.8	233
130	Antisynthetase Syndrome with Anti-Jo1 Antibodies in 48 Patients: Pulmonary Involvement Predicts Disease-modifying Antirheumatic Drug Use. Journal of Rheumatology, 2012, 39, 1835-1839.	2.0	48
131	Quadriceps strength is a sensitive marker of disease progression in sporadic inclusion body myositis. Neuromuscular Disorders, 2012, 22, 980-986.	0.6	43
132	Interleukinâ€21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis and Rheumatism, 2012, 64, 2001-2011.	6.7	147
133	Myositis or dystrophy? Traps and pitfalls. Presse Medicale, 2011, 40, e249-e255.	1.9	53
134	Inflammatory or necrotizing myopathies, myositides and other acquired myopathies, new insight in 2011. Presse Medicale, 2011, 40, e197-e198.	1.9	12
135	Infectious Complications in Polymyositis and Dermatomyositis: A Series of 279 Patients. Seminars in Arthritis and Rheumatism, 2011, 41, 48-60.	3.4	107
136	Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis and Rheumatism, 2011, 63, 1961-1971.	6.7	168
137	A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-associated Virus (AAV) Types 1, 2, 6, and 8. Molecular Therapy, 2011, 19, 2084-2091.	8.2	163
138	Long-term observational study of sporadic inclusion body myositis. Brain, 2011, 134, 3176-3184.	7.6	319
139	Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors. Human Gene Therapy, 2010, 21, 704-712.	2.7	776
140	Endocarditis Due to Neisseria bacilliformis in a Patient with a Bicuspid Aortic Valve. Journal of Clinical Microbiology, 2009, 47, 1973-1975.	3.9	22
141	Role of Regulatory T Cells in a New Mouse Model of Experimental Autoimmune Myositis. American Journal of Pathology, 2009, 174, 989-998.	3.8	74
142	Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies. Annals of the New York Academy of Sciences, 2008, 1132, 84-92.	3.8	93
143	Distal inflammatory myopathy: Unusual presentation of polymyositis or new entity?. Neuromuscular Disorders, 2008, 18, 493-500.	0.6	6
144	Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscular Disorders, 2006, 16, 334-336.	0.6	84

#	Article	IF	Citations
145	Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis. Brain, 2006, 129, 986-995.	7.6	65
146	MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. Journal of Neuroimmunology, 2005, 170, 41-48.	2.3	55
147	Mechanisms Involved in the Lowâ€Level Regeneration of CD4+Cells in HIVâ€1â€“Infected Patients Receiving Highly Active Antiretroviral Therapy Who Have Prolonged Undetectable Plasma Viral Loads. Journal of Infectious Diseases, 2005, 191, 1670-1679.	4.0	115
148	Phase I Study of Dystrophin Plasmid-Based Gene Therapy in Duchenne/Becker Muscular Dystrophy. Human Gene Therapy, 2004, 15, 1065-1076.	2.7	134
149	IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. Clinical Immunology, 2004, 111, 241-251.	3.2	49
150	Sarcoidosis and interferon therapy: report of five cases and review of the literature. European Journal of Internal Medicine, 2003, 14, 237-243.	2.2	58
151	Paradoxical intracranial cryptococcoma in a human immunodeficiency virusâ€“infected man being treated with combination antiretroviral therapy. American Journal of Medicine, 2002, 113, 155-157.	1.5	40
152	Severe Perturbations of the Blood T Cell Repertoire in Polymyositis, But Not Dermatomyositis Patients. Journal of Immunology, 2001, 167, 3521-3529.	0.8	87
153	Successful Percutaneous Dihydrotestosterone Treatment of Gynecomastia Occurring during Highly Active Antiretroviral Therapy: Four Cases and a Review of the Literature. Clinical Infectious Diseases, 2001, 33, 891-893.	5.8	28
154	Two Episodes of Acute Renal Failure, Rhabdomyolysis, and Severe Hepatitis in an AIDS Patient Successively Treated with Ritonavir and Indinavir. Clinical Infectious Diseases, 1999, 28, 1180-1181.	5.8	23
155	Lack of Interleukin 10 Expression in Monocyte-Derived Macrophages in Response toin VitroInfection by HIV Type 1 Isolates. AIDS Research and Human Retroviruses, 1997, 13, 961-966.	1.1	17
156	Cytokine mRNA levels in unmanipulated (ex vivo) and in vitro stimulated monkey PBMCs using a semi-quantitative RT-PCR and high sensitivity fluorescence-based detection strategy. Cytokine, 1996, 8, 32-41.	3.2	31
157	Interleukin 1Î², Interleukin 6, Tumor Necrosis Factor Î±, and Interleukin 10 Responses in Peripheral Blood Mononuclear Cells of Cynomolgus Macaques during Acute Infection with SIVmac251. AIDS Research and Human Retroviruses, 1996, 12, 241-250.	1.1	30
158	Cytokine mRNA Expression in Mononuclear Cells from Different Tissues during Acute SIVmac251 Infection of Macaques. AIDS Research and Human Retroviruses, 1996, 12, 1263-1272.	1.1	39
159	Functional Consequences of Macrophage Infection by Human Immunodeficiency Virus: Bispecific Antibody Targeting of HIV-1-Infected Cells to FcÎ³RI Expressing Effector Cells. Stem Cells and Development, 1995, 4, 579-585.	1.0	2
160	Tumor necrosis factorâ€alpha in serum of macaques during SIV_{mac251} acute infection. Journal of Medical Primatology, 1995, 24, 94-100.	0.6	12
161	Nef and Gag Synthetic Peptide Priming of Antibody Responses to HIV Type 1 Antigens in Mice and Primates. AIDS Research and Human Retroviruses, 1994, 10, 1241-1250.	1.1	6
162	Four cross-linked HIV Gag peptides prime the immune response to HIV proteins in mice. Peptides, 1994, 15, 935-943.	2.4	0